Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Apr;37(4):818–824. doi: 10.1128/aac.37.4.818

Comparative pharmacokinetics of two prodrugs of zidovudine in rabbits: enhanced levels of zidovudine in brain tissue.

R H Lupia 1, N Ferencz 1, J J Lertora 1, S K Aggarwal 1, W J George 1, K C Agrawal 1
PMCID: PMC187771  PMID: 8494380

Abstract

The pharmacokinetics of two prodrugs of zidovudine (AZT), 1,4-dihydro-1-methyl-3-[(pyridylcarbonyl)oxy] ester and isoleucinyl ester (DPAZT and IAZT, respectively), were investigated in a rabbit model to determine their potential utility as drugs against human immunodeficiency virus. Drugs were administered by intravenous infusion over 5 min at doses equal to 10 mg of AZT per kg of body weight. The levels of the prodrugs and of released AZT in plasma, cerebrospinal fluid (CSF), and brain were determined by high-performance liquid chromatography analysis. DPAZT disappeared rapidly from plasma, whereas IAZT maintained a sustained level in plasma for up to 4 h. The levels in plasma of AZT released from DPAZT were consistently lower than the levels of AZT released from IAZT or AZT itself. At 75 min after infusion of AZT, DPAZT, and IAZT, the CSF plasma AZT ratios were 0.23, 0.30, and 0.25, while the brain/CSF AZT ratios were 0.32, 0.63, and 0.64, respectively. These results indicate that the administration of each of the prodrugs produced a higher concentration of AZT in the brain than did the direct administration of AZT. Both prodrugs therefore may be superior to AZT itself with respect to achieving anti-human immunodeficiency virus concentrations within the central nervous system.

Full text

PDF
818

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aggarwal S. K., Gogu S. R., Rangan S. R., Agrawal K. C. Synthesis and biological evaluation of prodrugs of zidovudine. J Med Chem. 1990 May;33(5):1505–1510. doi: 10.1021/jm00167a034. [DOI] [PubMed] [Google Scholar]
  2. Ayre S. G., Skaletski B., Mosnaim A. D. Blood-brain barrier passage of azidothymidine in rats: effect of insulin. Res Commun Chem Pathol Pharmacol. 1989 Jan;63(1):45–52. [PubMed] [Google Scholar]
  3. Chu C. K., Bhadti V. S., Doshi K. J., Etse J. T., Gallo J. M., Boudinot F. D., Schinazi R. F. Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine. J Med Chem. 1990 Aug;33(8):2188–2192. doi: 10.1021/jm00170a023. [DOI] [PubMed] [Google Scholar]
  4. Eilbott D. J., Peress N., Burger H., LaNeve D., Orenstein J., Gendelman H. E., Seidman R., Weiser B. Human immunodeficiency virus type 1 in spinal cords of acquired immunodeficiency syndrome patients with myelopathy: expression and replication in macrophages. Proc Natl Acad Sci U S A. 1989 May;86(9):3337–3341. doi: 10.1073/pnas.86.9.3337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Elder G. A., Sever J. L. AIDS and neurological disorders: an overview. Ann Neurol. 1988;23 (Suppl):S4–S6. doi: 10.1002/ana.410230705. [DOI] [PubMed] [Google Scholar]
  6. Gogu S. R., Aggarwal S. K., Rangan S. R., Agrawal K. C. A pro-drug of zidovudine with enhanced efficacy against human immunodeficiency virus. Biochem Biophys Res Commun. 1989 Apr 28;160(2):656–661. doi: 10.1016/0006-291x(89)92483-2. [DOI] [PubMed] [Google Scholar]
  7. Ho D. D., Rota T. R., Schooley R. T., Kaplan J. C., Allan J. D., Groopman J. E., Resnick L., Felsenstein D., Andrews C. A., Hirsch M. S. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med. 1985 Dec 12;313(24):1493–1497. doi: 10.1056/NEJM198512123132401. [DOI] [PubMed] [Google Scholar]
  8. Klecker R. W., Jr, Collins J. M., Yarchoan R., Thomas R., Jenkins J. F., Broder S., Myers C. E. Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther. 1987 Apr;41(4):407–412. doi: 10.1038/clpt.1987.49. [DOI] [PubMed] [Google Scholar]
  9. Koenig S., Gendelman H. E., Orenstein J. M., Dal Canto M. C., Pezeshkpour G. H., Yungbluth M., Janotta F., Aksamit A., Martin M. A., Fauci A. S. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science. 1986 Sep 5;233(4768):1089–1093. doi: 10.1126/science.3016903. [DOI] [PubMed] [Google Scholar]
  10. Palomino E., Kessel D., Horwitz J. P. A dihydropyridine carrier system for sustained delivery of 2',3'-dideoxynucleosides to the brain. J Med Chem. 1989 Mar;32(3):622–625. doi: 10.1021/jm00123a020. [DOI] [PubMed] [Google Scholar]
  11. Price R. W., Brew B., Sidtis J., Rosenblum M., Scheck A. C., Cleary P. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science. 1988 Feb 5;239(4840):586–592. doi: 10.1126/science.3277272. [DOI] [PubMed] [Google Scholar]
  12. Richman D. D., Fischl M. A., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Hirsch M. S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. doi: 10.1056/NEJM198707233170402. [DOI] [PubMed] [Google Scholar]
  13. Schenkman J. B., Cinti D. L. Preparation of microsomes with calcium. Methods Enzymol. 1978;52:83–89. doi: 10.1016/s0076-6879(78)52008-9. [DOI] [PubMed] [Google Scholar]
  14. Terasaki T., Pardridge W. M. Restricted transport of 3'-azido-3'-deoxythymidine and dideoxynucleosides through the blood-brain barrier. J Infect Dis. 1988 Sep;158(3):630–632. doi: 10.1093/infdis/158.3.630. [DOI] [PubMed] [Google Scholar]
  15. Torrence P. F., Kinjo J., Lesiak K., Balzarini J., De Clercq E. AIDS dementia: synthesis and properties of a derivative of 3'-azido-3'-deoxythymidine (AZT) that may become 'locked' in the central nervous system. FEBS Lett. 1988 Jul 4;234(1):135–140. doi: 10.1016/0014-5793(88)81319-x. [DOI] [PubMed] [Google Scholar]
  16. Wiley C. A., Schrier R. D., Nelson J. A., Lampert P. W., Oldstone M. B. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A. 1986 Sep;83(18):7089–7093. doi: 10.1073/pnas.83.18.7089. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES